322 related articles for article (PubMed ID: 2196168)
1. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
Friedel HA; Brogden RN
Drugs; 1990 Jun; 39(6):929-67. PubMed ID: 2196168
[TBL] [Abstract][Full Text] [Related]
2. Double-blind comparator trials with pinacidil, a potassium channel opener.
Callaghan JT; Goldberg MR; Brunelle R
Drugs; 1988; 36 Suppl 7():77-82. PubMed ID: 3076139
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evaluation of pinacidil in hypertension.
Ramsay LE; Freestone S
Br J Clin Pharmacol; 1983 Sep; 16(3):336-8. PubMed ID: 6626426
[TBL] [Abstract][Full Text] [Related]
4. Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.
Carlsen JE; Jensen HA; Rehling M; Lund JO; Trap-Jensen J
Drugs; 1988; 36 Suppl 7():55-63. PubMed ID: 3076136
[TBL] [Abstract][Full Text] [Related]
5. The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice.
Sterndorff B; Johansen P
Acta Med Scand; 1988; 224(4):329-36. PubMed ID: 3188983
[TBL] [Abstract][Full Text] [Related]
6. Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group.
Fletcher AE; Battersby C; Adnitt P; Underwood N; Jurgensen HJ; Bulpitt CJ
J Cardiovasc Pharmacol; 1992 Jul; 20(1):108-14. PubMed ID: 1383618
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.
Zachariah PK; Sheps SG; Schirger A; Fisher LD; Shub C; Collins JB; Spiekerman RE
Eur J Clin Pharmacol; 1986; 31(2):133-41. PubMed ID: 3803413
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of vasodilators. Part I.
Kirsten R; Nelson K; Kirsten D; Heintz B
Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
Goldberg MR
J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
[TBL] [Abstract][Full Text] [Related]
10. [Potassium channel activators. Perspectives in the treatment of arterial hypertension].
Giudicelli JF; Richer C; Berdeaux A
Presse Med; 1991 Jan; 20(2):75-81. PubMed ID: 1825708
[TBL] [Abstract][Full Text] [Related]
11. Pinacidil: history, basic pharmacology, and therapeutic implications.
Ahnfelt-Rønne I
J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S1-4. PubMed ID: 2466172
[TBL] [Abstract][Full Text] [Related]
12. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
[TBL] [Abstract][Full Text] [Related]
13. Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension.
Finnerty FA; Brogden RN
Drugs; 1985 Jul; 30(1):22-31. PubMed ID: 3896742
[TBL] [Abstract][Full Text] [Related]
14. Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
Koliopoulos K; Papadoyannis DE; Karatzas NB
Eur J Clin Pharmacol; 1984; 27(3):287-9. PubMed ID: 6510455
[TBL] [Abstract][Full Text] [Related]
15. Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.
Steensgaard-Hansen F; Carlsen JE
Drugs; 1988; 36 Suppl 7():70-6. PubMed ID: 3254831
[TBL] [Abstract][Full Text] [Related]
16. Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
Goldberg MR; Offen WW
Drugs; 1988; 36 Suppl 7():83-92. PubMed ID: 3076140
[TBL] [Abstract][Full Text] [Related]
17. Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
Sterndorff B; Johansen P
Drugs; 1988; 36 Suppl 7():64-6. PubMed ID: 3076137
[No Abstract] [Full Text] [Related]
18. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
McTavish D; Young RA; Clissold SP
Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
[TBL] [Abstract][Full Text] [Related]
19. K(+)-channel openers: new antihypertensive drugs?
Haeusler G
Clin Physiol Biochem; 1990; 8 Suppl 2():46-56. PubMed ID: 2095310
[TBL] [Abstract][Full Text] [Related]
20. Treating essential hypertension. The first choice is usually a thiazide diuretic.
Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
